Terazosin Hydrochloride
Product Images NDC 53808-0307

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 53808-0307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Terazosin HCl 1 mg Caps (Terazosin 1mg(cadista))

FDA Label Image

Terazosin HCl 2 mg Caps (Terazosin 2mg(cadista))

FDA Label Image

Terazosin HCl 5 mg Caps (Terazosin 5mg(cadista))

FDA Label Image

Chemical Structure (Terazosin Hydrochloride Capsules 1)

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

Figure 1 (Terazosin Hydrochloride Capsules 2)
This appears to be a figure/ table caption from a study (Study 1) that is evaluating the mean change in Total Symptom Score and Peak Flow Rate from baseline for Terazosin medication. The values and comparison results are provided in the table.*
FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

Figure 2 (Terazosin Hydrochloride Capsules 3)
This is a graph that displays the mean change in total symptom score from baseline in a long-term, open-label, non-placebo controlled study involving 494 participants. The study was conducted over a period of 30 months, and the graph shows the mean change in symptom score at months 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30. The baseline mean for symptom score was 10.7, and there was a significant improvement in symptom score at each time point compared to baseline.*
FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

Figure 3 (Terazosin Hydrochloride Capsules 4)
This is a graph displaying the mean change in peak flow rate from baseline in a long-term, open-label, non-placebo controlled study. The x-axis shows the number of months (from 0 to 30), while the y-axis represents the mean change from baseline. The baseline mean is 99 and there is a statistically significant change at month 27.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.